Many CRISPR enzymes can be useful in biomedical applications to recognize biomarkers of infectious and non-infectious diseases (viruses, bacteria, etc.), as well as cancer and many other diseases that in some way involve a nucleic acid sequence (either RNA or DNA).
CRISPR systems are usually used for genome editing, but they can also be used in applications that have no genome editing component. One of the more recent applications of CRISPR is in identification of pathogens causing infectious diseases, using enzymes in the Cas9, Cas12, Cas13, and Cas14 families, many of which are still in the research phase.
Cas9 methods for pathogen identification can be divided into those that use enzymatically active Cas9 and those that use catalytically inactive (dead) Cas9, known as dCas9 [2, 3]. All the Cas9-based methods of pathogen identification can theoretically identify any DNA sequence having a Cas9 target site and PAM sequence. Another way Cas9 can be used in recognition of the disease-causing microorganisms is by cleavage of a pathogen’s genomic DNA into pieces sized appropriately for next generation sequencing .
The “PC” (which stands for “paired dCas9”) reporter system is an example of a system using dCas9. This technique consists of 2 molecules of dCas9 each connected to a half-molecule of firefly luciferase. When both dCas9 molecules are directed by guide RNA (gRNA) to pre-specified DNA sequences near each other in the genome of the pathogen of interest, the 2 halves of the luciferase come together, and light is emitted . The PC reporter system is extremely sensitive, finding as little as 1 molecule of DNA  and was shown to identify the DNA sequence for tuberculosis  and likely any DNA sequence, as long as there are 2 good target sequences at an appropriate distance from each other.
There are several Cas12, Cas13, and Cas14 enzymes. Identification methods have been developed using several of these enzymes, including Cas12a, Cas12b, Cas13a, Cas13b, Cas13d, and Cas14a from a wide variety of bacterial species. Some of these techniques use several of these enzymes simultaneously, allowing multiplexing assays for the purpose of distinguishing pathogens.
The Cas12-, Cas13-, and Cas14-based techniques depend on a process known as collateral cleavage. That is, when one of these enzymes binds its target as directed by gRNA, the enzyme cleaves not only the target but also other nucleic acids nearby in the solution.
Cutting by a CRISPR enzyme is often not perfect and can result in cleavage of other things. Cas12-, Cas13-, and Cas14-based methods are rapidly growing in popularity and these technologies depend on collateral cleavage (also called “trans cleavage”), a process in which Cas enzymes cut not only the target DNA or RNA but also a large number of unrelated DNA or RNA molecules nearby in solution. Because labeled RNA or DNA can be added to the assay, this process allows for significant signal amplification [6, 7].
The SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) technique has been developed for identification of RNA sequences, and DETECTR (DNA endonuclease-targeted CRISPR trans reporter) for DNA detection . Both SHERLOCK and DETECTR require isothermal amplification of the target sequence before the CRISPR cleavage step to obtain sufficient quantities of relevant sequences for identification. In SHERLOCK, the isothermal amplification step is followed by T7 transcription to generate RNA. In DETECTR, T7 transcription is not performed, as DNA is targeted instead of RNA. Standard DETECTR uses LbCas12a, which requires a PAM site, whereas SHERLOCK uses 1 or more Cas13 enzymes and other enzymes, removing the requirement for a PAM site . There is also a modification of DETECTR that uses Cas14a, which too removes the need for a PAM site . DETECTR has been shown to differentiate between 2 forms of human papilloma virus (HPV) . SHERLOCK has been shown to identify Zika and dengue viruses, and to identify different mutations in liquid biopsies from non-small cell lung cancer patients .